HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma

Nature Medicine

Volumn 22, Issue 10, 2016, Pages 1180-1186

  Tavana, Omid ^a   Li, Dawei ^a   Dai, Chao ^a   Lopez, Gonzalo ^a   Banerjee, Debarshi ^a   Kon, Ning ^a   Chen, Chao ^b   Califano, Andrea ^a   Yamashiro, Darrell J ^a   Sun, Hongbin ^b   Gu, Wei ^a  

^a Columbia University ^*  (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEUBIQUITINASE; MYC PROTEIN; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG; N MYC PROTO ONCOGENE PROTEIN; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN; USP7 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CANCER PROGNOSIS; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UBIQUITINATION; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, KNOCKOUT; N-MYC PROTO-ONCOGENE PROTEIN; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITIN THIOLESTERASE; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84987673668     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4180     Document Type: Article

References (42)

1. Dang, C. V. MYC on the path to cancer. Cell 149, 22-35 (2012).
2. Conacci-Sorrell, M., McFerrin, L. & Eisenman, R. N. An overview of MYC and its interactome. Cold Spring Harb. Perspect. Med. 4, a014357 (2014).
3. Popov, N. et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat. Cell Biol. 9, 765-774 (2007).
4. Otto, T. et al. Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma. Cancer Cell 15, 67-78 (2009).
5. Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653 (2002).
6. Li, M., Brooks, C. L., Kon, N. & Gu, W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13, 879-886 (2004).
7. Hu, M. et al. Crystal structure of a UBP family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111, 1041-1054 (2002).
8. Nicholson, B. & Suresh Kumar, K. G. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem. Biophys. 60, 61-68 (2011).
9. van der Horst, A. et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7 (HAUSP). Nat. Cell Biol. 8, 1064-1073 (2006).
10. Song, M. S. et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813-817 (2008).
11. Du, Z. et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci. Signal. 3, ra80 (2010).
12. Faesen, A. C. et al. Mechanism of USP7 (HAUSP) activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP synthetase. Mol. Cell 44, 147-159 (2011).
13. Lee, H. R. et al. Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein. Nat. Struct. Mol. Biol. 18, 1336-1344 (2011).
14. Ma, H. et al. M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability. Proc. Natl. Acad. Sci. USA 109, 4828-4833 (2012).
15. Colleran, A. et al. Deubiquitination of NF-B by ubiquitin-specific protease 7 promotes transcription. Proc. Natl. Acad. Sci. USA 110, 618-623 (2013).
16. Cheng, C., Niu, C., Yang, Y., Wang, Y. & Lu, M. Expression of HAUSP in gliomas correlates with disease progression and survival of patients. Oncol. Rep. 29, 1730-1736 (2013).
17. Pfoh, R., Lacdao, I. K. & Saridakis, V. Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr. Relat. Cancer 22, T35-T54 (2015).
18. Kon, N. et al. Roles of HAUSP-mediated p53 regulation in central nervous system development. Cell Death Differ. 18, 1366-1375 (2011).
19. Eilers, M. & Eisenman, R. N. Myc's broad reach. Genes Dev. 22, 2755-2766 (2008).
20. Dang, C. V. MYC, metabolism, cell growth and tumorigenesis. Cold Spring Harb. Perspect. Med. 3, a014217 (2013).
21. Charron, J. et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev. 6, 12A, 2248-2257 (1992).
22. Stanton, B. R., Perkins, A. S., Tessarollo, L., Sassoon, D. A. & Parada, L. F. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 6, 12A, 2235-2247 (1992).
23. Sawai, S. et al. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 117, 1445-1455 (1993).
24. Knoepfler, P. S., Cheng, P. F. & Eisenman, R. N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev. 16, 2699-2712 (2002).
25. Arvanitis, C. & Felsher, D. W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin. Cancer Biol. 16, 313-317 (2006).
26. Colland, F. et al. Small-molecule inhibitor of USP7 (HAUSP) ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8, 2286-2295 (2009).
27. Altun, M. et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 18, 1401-1412 (2011).
28. Reverdy, C. et al. Discovery of specific inhibitors of human USP7 (HAUSP) deubiquitinating enzyme. Chem. Biol. 19, 467-477 (2012).
29. Chauhan, D. et al. A small-molecule inhibitor of ubiquitin-specific protease 7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345-358 (2012).
30. Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279-284 (2013).
31. Valentijn, L. J. et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 109, 19190-19195 (2012).
32. Kim, E. S. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99, 11399-11404 (2002).
33. Choi, S. H., Wright, J. B., Gerber, S. A. & Cole, M. D. Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev. 24, 1236-1241 (2010).
34. Sjostrom, S. K., Finn, G., Hahn, W. C., Rowitch, D. H. & Kenney, A. M. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev. Cell 9, 327-338 (2005).
35. Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 101, 9085-9090 (2004).
36. Zhao, X. et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat. Cell Biol. 10, 643-653 (2008).
37. Brockmann, M. et al. Small-molecule inhibitors of aurora-A induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24, 75-89 (2013).
38. Gustafson, W. C. et al. Drugging MYCN through an allosteric transition in aurora kinase A. Cancer Cell 26, 414-427 (2014).
39. Cummins, J. M. & Vogelstein, B. HAUSP is required for p53 destabilization. Cell Cycle 3, 689-692 (2004).
40. Kon, N. et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29, 1270-1279 (2010).
41. Rader, J. et al. Dual CDK4-CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin. Cancer Res. 19, 6173-6182 (2013).
42. Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838-847 (2016).